Site Editor
Leo I. Gordon, MD, FACP
Leo I. Gordon, MD, FACP
Posted: Monday, April 18, 2022
For patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), treatment with the antibody-drug conjugate loncastuximab tesirine-lpyl improved the overall health state and health-related quality of life (HRQOL) across all age groups, according to an open-label, phase II study (LOTIS 2) presented at the 2022 National Comprehensive Cancer Network Annual Conference (Abstract HSR22-171). Significant improvement was evident in patients older than 75, who reported declines in pain, lumps and swelling, and weight loss, explained Mehdi Hamadani, MD, of the Medical College of Wisconsin, Milwaukee, and colleagues. These findings were also published in JNCCN–Journal of the National Comprehensive Cancer Network.
From 2018 to 2021, a total of 130 patients with DLBCL were recruited for the study. Patients were either younger than 65 (n = 57), between the ages of 65 and 74 (n = 53), or 75 and older (n = 20). All patients had a baseline HRQOL score recorded before treatment using the EQ-5D visual analog scale (VAS) and Functional Assessment of Cancer Treatment–Lymphoma (FACT–Lym). Patients were administered an intravenous infusion of loncastuximab tesirine on day 1 of a 3-week treatment cycle. HRQOL scores were then reassessed.
The study findings revealed stability or improvement in the EQ-5D VAS and FACT–Lym scores over the duration of treatment across all patient groups. In addition, all patients reported generalized improvement in pain, lumps and swelling, and weight loss after treatment. This improvement was most pronounced in patients aged 75 or older. Furthermore, most patients reported mild or no side effects of treatment, with patients aged 75 or older being the least affected by adverse effects.
Disclosure: The study was funded by ADC Therapeutics. Several of the study authors are employees of ADC Therapeutics, and others have served as a consultant to, received honoraria from, or received institutional research from ADC Therapeutics.
JNCCN–Journal of the National Comprehensive Cancer Network
JNCCN Spotlights
